Equity Overview
Price & Market Data
Price: $1.42
Daily Change: +$0.08 / 5.63%
Range: $1.28 - $1.47
Market Cap: $132,367,760
Volume: 2,442,204
Performance Metrics
1 Week: 6.87%
1 Month: 18.64%
3 Months: 38.61%
6 Months: 20.69%
1 Year: -14.11%
YTD: 34.62%
Company Details
Employees: 15
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.